Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
With countless preclinical studies on block copolymer micelles (BCMs) successfully demonstrating the superiority of these advanced drug delivery formulations over conventional formulations, it remains somehow discouraging that only a few have reached clinical evaluation and practice. With a critical eye, this review aims to compare and summarize the preclinical and clinical data available on several BCM formulations and to identify their primary role in drug delivery as "carrier" or "solubilizer". This review focuses on polymeric micelles that have reached clinical evaluation and/or are being pursued commercially. Where available, we aim to compare the pharmacokinetics, toxicity, and efficacy data obtained in preclinical studies to identify the factors that likely played a key role in a decision to move these formulations forward from the bench to a first-in-human trial. Finally, we summarize clinical data obtained to date, where available, and conclude with the impact that each formulation has had on patients in terms of safety and efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several polymeric micelle formulations have reached the clinical stage and are either in clinical trials or are approved for human use.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [13]
In the citing paper
“Based on these functionalities derived from the polymer formulations, the overall PK profile of the therapeutic compounds such as maximum systemic concentration, area under the curve (AUC), clearance (CL), volume of distribution (Vd), and biodistribution can be improved [13].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [13]
In the citing paper
“A phase I clinical trial was conducted in South Korea (NCT01336582) and it was reported that Nanoxel® M (70 mg/m2) exhibited an improved drug safety profile compared to the conventional docetaxel formulation in patients with advanced solid tumors [13].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [13]
In the citing paper
“Additionally, amphiphilic polymers used for micelles preparation can interact with biological membranes and display inherent biological activity: it is well known the inhibitory effect of several polymers on the efflux pumps responsible for MDR in chemotherapy [22,23].”
From Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions (2021) · cites this paper as [23]
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., Clarke-Pearson, D. L., & Insalaco, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401502 · Cited by 2,658
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Block copolymer micelles: preparation, characterization and application in drug delivery
Gaucher, G., Dufresne, M.-H., Sant, V. P., Kang, N., Maysinger, D., & Leroux, J.-C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.034 · Cited by 1,498
Nano-engineering block copolymer aggregates for drug delivery
Allen, C., Maysinger, D., & Eisenberg, A. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00058-2 · Cited by 1,358
Self-citationEffects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260805 · Cited by 1,277
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Owen, S. C., Chan, D. P. Y., & Shoichet, M. S. (2012) · Nano Today · doi:10.1016/j.nantod.2012.01.002 · Cited by 911
Block copolymer micelles as vehicles for drug delivery
Kazunori, K., Glenn S., K., Masayuki, Y., Teruo, O., & Yasuhisa, S. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90172-2 · Cited by 877
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991210)83:6<870::aid-ijc35>3.0.co;2-9 · Cited by 860
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 710
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Perry, J. L., Reuter, K. G., Kai, M. P., Herlihy, K. P., Jones, S. W., Luft, J. C., Napier, M., Bear, J. E., & DeSimone, J. M. (2012) · Nano Letters · doi:10.1021/nl302638g · Cited by 606
Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575
Development of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Targeted polymeric micelles for delivery of poorly soluble drugs
Torchilin, V. P. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4153-5 · Cited by 543
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430
Development of amphiphilic diblock copolymers as micellar carriers of taxol
Zhang, X., Jackson, J. K., & Burt, H. M. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)04386-1 · Cited by 402
Particular aspects of platinum compounds used at present in cancer treatment
Desoize, B., & Madoulet, C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00219-0 · Cited by 393
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
Odyssey of a cancer nanoparticle: From injection site to site of action
Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 364
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm374 · Cited by 356
Szebeni, J., Alving, C. R., & Muggia, F. M. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.4.300 · Cited by 341
Mikhail, A. S., & Allen, C. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.010 · Cited by 328
Self-citationPolyester-based micelles and nanoparticles for the parenteral delivery of taxanes
Gaucher, G., Marchessault, R. H., & Leroux, J.-C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.012 · Cited by 315
Yokoyama, M. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00115-6 · Cited by 308
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603855 · Cited by 290
Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
Stewart, L. A., Aabo, K., Adnitt, P. I., Adams, M., Alberts, D. S., Barley, V., Bell, D. R., Bianchi, U., Blessing, J. A., Buyse, M. E., et al. (1991) · Cited by 270
Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials
Alakhov, V., Klinski, E., Li, S., Pietrzynski, G., Venne, A., Batrakova, E., Bronitch, T., & Kabanov, A. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00064-8 · Cited by 266
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., & Papadimitriou, C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.011 · Cited by 261
Burt, H. M., Zhang, X., Toleikis, P., Embree, L., & Hunter, W. L. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00067-3 · Cited by 254
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
Stirland, D. L., Nichols, J. W., Miura, S., & Bae, Y. H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.026 · Cited by 225
Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bunger, R., Laverman, P., Metselaar, J. M., Storm, G., Chanan-Khan, A., Liebes, L., et al. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120004790 · Cited by 212
Cabral, H., Nishiyama, N., Okazaki, S., Koyama, H., & Kataoka, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.022 · Cited by 201
Lee, S.-W., Yun, M.-H., Jeong, S. W., In, C.-H., Kim, J.-Y., Seo, M.-H., Pai, C.-M., & Kim, S.-O. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.012 · Cited by 169
Cabral, H., Nishiyama, N., & Kataoka, K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.024 · Cited by 161
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review
Stordal, B., Pavlakis, N., & Davey, R. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.009 · Cited by 159
Mikhail, A. S., Eetezadi, S., & Allen, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062630 · Cited by 144
Self-citationSingle agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
Chollet, P. J. M., Bensmaïne, M. A., Brienza, S., Deloche, C., Curé, H., Caillet, H., & Cvitkovic, E. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010500 · Cited by 134
Park, I. H., Sohn, J. H., Kim, S. B., Lee, K. S., Chung, J. S., Lee, S. H., Kim, T. Y., Jung, K. H., Cho, E. K., Kim, Y. S., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.289 · Cited by 133
Zhao, Y., Alakhova, D. Y., Kim, J. O., Bronich, T. K., & Kabanov, A. V. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.02.026 · Cited by 125
Endo, K., Ueno, T., Kondo, S., Wakisaka, N., Murono, S., Itō, M., Kataoka, K., Kato, Y., & Yoshizaki, T. (2012) · Cancer Science · doi:10.1111/cas.12079 · Cited by 119
Tsukioka, Y., Matsumura, Y., Hamaguchi, T., Koike, H., Moriyasu, F., & Kakizoe, T. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01217.x · Cited by 114
Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel
Zhang, X., Burt, H. M., Mangold, G., Dexter, D., Hoff, D. V., Mayer, L., & Hunter, W. L. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199708000-00008 · Cited by 112
Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy
Gabizón, A., Shmeeda, H., & Grenader, T. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.09.006 · Cited by 112
Hu, Q., Rijcken, C. J. F., Bansal, R., Hennink, W. E., Storm, G., & Prakash, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.085 · Cited by 110
Block copolymeric biotransport carriers as versatile vehicles for drug delivery
Alakhov, V. Y., & Kabanov, A. V. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.9.1453 · Cited by 104
Access to cancer medications in low- and middle-income countries
Lopes, G. D. L., Jr., de Souza, J. A., & Barrios, C. H. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.55 · Cited by 104
Negishi, T., Koizumi, F., Uchino, H., Kuroda, J., Kawaguchi, T., Naito, S., & Matsumura, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603311 · Cited by 92
The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®)
Szebeni, J., Baranyi, L., Savay, S., Lutz, H. U., Jelezarova, E., Bunger, R., & Alving, C. R. (2000) · Journal of Liposome Research · doi:10.3109/08982100009031112 · Cited by 90
Saif, M. W., Podoltsev, N. A., Rubin, M. S., Figueroa, J. A., Lee, M. Y., Kwon, J., Rowen, E., Yu, J., & Kerr, R. O. (2009) · Cancer Investigation · doi:10.3109/07357900903179591 · Cited by 89
Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs
Baba, M., Matsumoto, Y., Kashio, A., Cabral, H., Nishiyama, N., Kataoka, K., & Yamasoba, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.026 · Cited by 77
Sakai-Kato, K., Nishiyama, N., Kozaki, M., Nakanishi, T., Matsuda, Y., Hirano, M., Hanada, H., Hisada, S., Onodera, H., Harashima, H., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.259 · Cited by 75
Ueno, T., Endo, K., Hori, K., Ozaki, N., Tsuji, A., Kondo, S., Wakisaka, N., Murono, S., Kataoka, K., Kato, Y., et al. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s60564 · Cited by 69
Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India
Ranade, A. A., Joshi, D. A., Phadke, G. K., Patil, P. P., Kasbekar, R. B., Apte, T. G., Dasare, R. R., Mengde, S. D., Parikh, P. M., Bhattacharyya, G. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt322 · Cited by 64
Madaan, A., Singh, P., Awasthi, A., Verma, R., Singh, A. T., Jaggi, M., Mishra, S. K., Kulkarni, S., & Kulkarni, H. S. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0883-2 · Cited by 52
Lee, S. Y., Park, H. S., Lee, K. Y., Kim, H. J., Jeon, Y. J., Jang, T. W., Lee, K. H., Kim, Y. C., Kim, K. S., Oh, I., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.11.005 · Cited by 26
Why I’m Holding onto Hope for Nano in Oncology
Allen, C. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00547 · Cited by 24
Self-citationSu, W., Chen, L., Li, C., Chen, J., Lin, Y., Choo, S. P., & Matsumura, Y. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)33328-7 · Cited by 15
van Gaal, E. V. B., & Crommelin, D. J. A. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-16241-6_2 · Cited by 12
Baur, M., van Oosterom, A. T., Dieras, V. C., Tubiana-Hulin, M., Coombes, R. C., Hatschek, T., Murawsky, M., Alakl, M., Hudec, M., & Dittrich, C. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0259-0 · Cited by 11
A novel nanopolymer based tumor targeted delivery system for paclitaxel
Singh, A. T., Jaggi, M., Khattar, D., Awasthi, A., Mishra, S. K., Tyagi, S., & Burman, A. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11095 · Cited by 11
Research works printed but not linked: 5
- Harrington K. J., 2001, Clin. Cancer Res., 7, 243
- 10.1002/(sici)1097-0215(19991210)83:6<848::aid-ijc29>3.3.co;2-r · doi:10.1002/(sici)1097-0215(19991210)83:6<848::aid-ijc29>3.3.co;2-r
- Nishiyama N., 2003, Cancer Res., 63, 8977
- Ibrahim N. K., 2002, Clin. Cancer Res., 8, 1038
- Weiss R. B., 1992, Semin. Oncol., 19, 670
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Ghezzi, M., Pescina, S., Padula, C., Santi, P., Del Favero, E., Cantù, L., & Nicoli, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.031 · Cited by 1,135
Lombardo, D., Kiselev, M. A., & Caccamo, M. T. (2019) · Journal of Nanomaterials · doi:10.1155/2019/3702518 · Cited by 864
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
“Based on these functionalities derived from the polymer formulations, the overall PK profile of the therapeutic compounds such as maximum systemic concentration, area under the curve (AUC), clearance (CL), volume of distribution (Vd), and biodistribution can be improved [13].”
BackgroundInfluentialNguyen, T.-T.-L., Duong, V.-A., & Maeng, H.-J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071103 · Cited by 252
Metadata
- Authors
- Houdaihed, L., Evans, J. C., & Allen, C.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Allen, Christine
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-05-18
- Volume
- 14
- Issue
- 8
- Pages
- 2503-2517
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2613525853
- Cited by
- 91
- References
- 75
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 14 · 2021: 14 · 2020: 15 · 2019: 13 · 2018: 9 · 2017: 2
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP325013)
- GlaxoSmithKline
- U.S. Department of Defense (11964460)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- block copolymer micelles, polymeric micelles, cancer therapy, drug delivery, clinical translation, pharmacokinetics, toxicity, drug solubilization
- MeSH terms
- Drug Carriers, Humans, Micelles, Polymers, Drug Delivery Systems, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.